Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hung Hung

Showing results (431-440 of 563) with videos related to

Pageof 57
Sort By:
Plos One|December 15, 2015
Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical TreatmentJen-Hao Yeh, Chao-Hung Hung, Jing-Houng Wang, et al.
Journal of Gastroenterology and Hepatology|April 10, 2014
Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosisMing-Chao Tsai, Hsien-Chung Yu, Chao-Hung Hung, et al.
Diagnostics (Basel, Switzerland)|February 11, 2023
Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral TherapyChun-Hsien Chen, Chien-Heng Shen, Kuo-Liang Wei, et al.
Oncotarget|December 2, 2017
Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavirChien-Hung Chen, Chuan-Mo Lee, Hsueh-Chou Lai, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2018
A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavirHung-Hsien Chiang, Chuan-Mo Lee, Tsung-Hui Hu, et al.
Journal of Gastroenterology and Hepatology|January 14, 2016
Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patientsHsin-Ming Wang, Chao-Hung Hung, Chuan-Mo Lee, et al.
International Journal of Cancer|August 13, 2015
Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virusChao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, et al.
Journal of Gastroenterology and Hepatology|March 8, 2018
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapyMing-Te Kuo, Po-Lin Tseng, Yeh-Pin Chou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 13, 2006
Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment responseChao-Hung Hung, Chuan-Mo Lee, Sheng-Nan Lu, et al.
Journal of Hepatology|December 17, 2008
The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipientsMing-Chao Tsai, Chien-Hung Chen, Chuan-Mo Lee, et al.
Pageof 57

Showing results (431-440 of 563) with videos related to

Sort By:
Pageof 57
Plos One|December 15, 2015
Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical TreatmentJen-Hao Yeh, Chao-Hung Hung, Jing-Houng Wang, et al.
Journal of Gastroenterology and Hepatology|April 10, 2014
Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosisMing-Chao Tsai, Hsien-Chung Yu, Chao-Hung Hung, et al.
Diagnostics (Basel, Switzerland)|February 11, 2023
Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral TherapyChun-Hsien Chen, Chien-Heng Shen, Kuo-Liang Wei, et al.
Oncotarget|December 2, 2017
Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavirChien-Hung Chen, Chuan-Mo Lee, Hsueh-Chou Lai, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2018
A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavirHung-Hsien Chiang, Chuan-Mo Lee, Tsung-Hui Hu, et al.
Journal of Gastroenterology and Hepatology|January 14, 2016
Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patientsHsin-Ming Wang, Chao-Hung Hung, Chuan-Mo Lee, et al.
International Journal of Cancer|August 13, 2015
Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virusChao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, et al.
Journal of Gastroenterology and Hepatology|March 8, 2018
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapyMing-Te Kuo, Po-Lin Tseng, Yeh-Pin Chou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 13, 2006
Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment responseChao-Hung Hung, Chuan-Mo Lee, Sheng-Nan Lu, et al.
Journal of Hepatology|December 17, 2008
The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipientsMing-Chao Tsai, Chien-Hung Chen, Chuan-Mo Lee, et al.
Pageof 57